Refine your search

Search Results

Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.

1 Study Matches

A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by a Long-Term Safety Extension Period in Children (Ages ≥ 2 Years to < 12 Years) With Atopic Dermatitis

Atopic Dermatitis (AD): Phase 3 double-blinded study, 8 week study with 44 week long-term safety period with guaranteed study medicine. Topical cream. Male and females ≥ 2 Years to < 12 Years with AD Atopic Dermatitis (AD), also known as eczema, is an inflammatory skin condition that can reoccur repeatedly. AD often causes itching and burning, skin flaking, and red bumps that can crust and open up. The purpose of this study is to find out of the study medicine, ruxolitinib cream, can help with the treatment of AD.
Samantha Gettle at sgettle2@pennstatehealth.psu.edu or 717-531-5136
All
Younger than 18 years old
This study is NOT accepting healthy volunteers
NCT04921969
Show full eligibility criteria
Hide eligibility criteria
Inclusion Criteria:
AD present for at least 3 months
AD covering between 3% and 20% body surface
Willing to follow all study guidelines
Exclusion Criteria:
Certain treatments for AD are not allowed; coordinator will discuss specific treatments
Positive for Hepatitis B, Hepatitis C, or HIV
Previous treatment with JAK inhibitors
Skin Conditions
  Email this study information to me
  Contact the study team
  See more information
  Show all 1 locations

Study Locations

Hide all locations
Location
Hershey, PA